Cm28, a scorpion toxin having a unique primary structure, inhibits KV1.2 and KV1.3 with high affinity
暂无分享,去创建一个
L. Possani | G. Panyi | F. Zamudio | Gustavo Delgado-Prudencio | M. Naseem | T. Szanto | Jesús Borrego | E. Carcamo-Noriega | José Beltrán-Vidal
[1] G. Tajti,et al. Optimization of Pichia pastoris Expression System for High-Level Production of Margatoxin , 2021, Frontiers in Pharmacology.
[2] Oriol Vinyals,et al. Highly accurate protein structure prediction with AlphaFold , 2021, Nature.
[3] N. Pastor,et al. Colombian Scorpion Centruroides margaritatus: Purification and Characterization of a Gamma Potassium Toxin with Full-Block Activity on the hERG1 Channel , 2021, Toxins.
[4] L. Pardo,et al. Discovery of KV1.3 ion channel inhibitors: Medicinal chemistry approaches and challenges , 2021, Medicinal research reviews.
[5] H. Drost,et al. Sensitive protein alignments at tree-of-life scale using DIAMOND , 2021, Nature Methods.
[6] O. Dym,et al. A molecular lid mechanism of K+ channel blocker action revealed by a cone peptide. , 2021, Journal of molecular biology.
[7] G. Tajti,et al. The Kv1.3 K+ channel in the immune system and its “precision pharmacology” using peptide toxins , 2021, Biologia Futura.
[8] Silvio C. E. Tosatto,et al. The InterPro protein families and domains database: 20 years on , 2020, Nucleic Acids Res..
[9] Silvio C. E. Tosatto,et al. Pfam: The protein families database in 2021 , 2020, Nucleic Acids Res..
[10] S. Gaál,et al. Shaker-IR K+ channel gating in heavy water: Role of structural water molecules in inactivation , 2016, The Journal of general physiology.
[11] A. Arcangeli,et al. Ion Channels Orchestrate Pancreatic Ductal Adenocarcinoma Progression and Therapy , 2021, Frontiers in Pharmacology.
[12] M. Gómez-Lim,et al. Cysteine‐Rich Peptides: Hyperstable Scaffolds for Protein Engineering , 2020, Chembiochem : a European journal of chemical biology.
[13] R. Norton,et al. The voltage-gated potassium channel KV1.3 as a therapeutic target for venom-derived peptides. , 2020, Biochemical pharmacology.
[14] S. Rangaraju,et al. Kv1.3 modulates neuroinflammation and neurodegeneration in Parkinson's disease. , 2020, The Journal of clinical investigation.
[15] Yonghua Ji,et al. Kv1.3 Channel as a Key Therapeutic Target for Neuroinflammatory Diseases: State of the Art and Beyond , 2020, Frontiers in Neuroscience.
[16] Olga Chernomor,et al. IQ-TREE 2: New Models and Efficient Methods for Phylogenetic Inference in the Genomic Era , 2019, bioRxiv.
[17] R. Efremov,et al. Kalium 2.0, a comprehensive database of polypeptide ligands of potassium channels , 2019, Scientific Data.
[18] A. Felipe,et al. Fighting rheumatoid arthritis: Kv1.3 as a therapeutic target. , 2019, Biochemical pharmacology.
[19] O. Dym,et al. Pore-modulating toxins exploit inherent slow inactivation to block K+ channels , 2019, Proceedings of the National Academy of Sciences.
[20] M Mirdita,et al. MMseqs2 desktop and local web server app for fast, interactive sequence searches , 2018, bioRxiv.
[21] L. Possani,et al. Kv1.3 channel blockade with the Vm24 scorpion toxin attenuates the CD4+ effector memory T cell response to TCR stimulation , 2018, Cell Communication and Signaling.
[22] R. Norton,et al. Structure, folding and stability of a minimal homologue from Anemonia sulcata of the sea anemone potassium channel blocker ShK , 2018, Peptides.
[23] E. De Pauw,et al. APETx4, a Novel Sea Anemone Toxin and a Modulator of the Cancer-Relevant Potassium Channel KV10.1 , 2017, Marine drugs.
[24] E. Muñoz-Elías,et al. Safety and pharmacodynamics of dalazatide, a Kv1.3 channel inhibitor, in the treatment of plaque psoriasis: A randomized phase 1b trial , 2017, PloS one.
[25] A. von Haeseler,et al. UFBoot2: Improving the Ultrafast Bootstrap Approximation , 2017, bioRxiv.
[26] Thomas K. F. Wong,et al. ModelFinder: Fast Model Selection for Accurate Phylogenetic Estimates , 2017, Nature Methods.
[27] D. Rokyta,et al. Venom‐gland transcriptomics and venom proteomics of the black‐back scorpion (Hadrurus spadix) reveal detectability challenges and an unexplored realm of animal toxin diversity , 2017, Toxicon : official journal of the International Society on Toxinology.
[28] Vijay S. Pande,et al. OpenMM 7: Rapid development of high performance algorithms for molecular dynamics , 2016, bioRxiv.
[29] T. Wise-Draper,et al. Kv1.3 Channels Mark Functionally Competent CD8+ Tumor-Infiltrating Lymphocytes in Head and Neck Cancer. , 2017, Cancer research.
[30] P. Herdewijn,et al. Structural and Functional Elucidation of Peptide Ts11 Shows Evidence of a Novel Subfamily of Scorpion Venom Toxins , 2016, Toxins.
[31] Y. Ji,et al. Mapping the Interaction Anatomy of BmP02 on Kv1.3 Channel , 2016, Scientific Reports.
[32] M. Péter,et al. 7DHC-induced changes of Kv1.3 operation contributes to modified T cell function in Smith-Lemli-Opitz syndrome , 2016, Pflügers Archiv - European Journal of Physiology.
[33] Kai-Chien Yang,et al. Mechanisms contributing to myocardial potassium channel diversity, regulation and remodeling. , 2016, Trends in cardiovascular medicine.
[34] K. Kövér,et al. An engineered scorpion toxin analogue with improved Kv1.3 selectivity displays reduced conformational flexibility , 2015, Scientific Reports.
[35] S. Feske,et al. Ion channels in innate and adaptive immunity. , 2015, Annual review of immunology.
[36] R. Norton,et al. Development of Highly Selective Kv1.3-Blocking Peptides Based on the Sea Anemone Peptide ShK , 2015, Marine drugs.
[37] Ernesto Ortiz,et al. Scorpion venom components as potential candidates for drug development , 2014, Toxicon.
[38] Z. Varga,et al. Margatoxin is a non-selective inhibitor of human Kv1.3 K+ channels. , 2014, Toxicon : official journal of the International Society on Toxinology.
[39] R. Norton,et al. A potent and Kv1.3-selective analogue of the scorpion toxin HsTX1 as a potential therapeutic for autoimmune diseases , 2014, Scientific Reports.
[40] Christine Beeton,et al. Ion channels and anti-cancer immunity , 2014, Philosophical Transactions of the Royal Society B: Biological Sciences.
[41] K. Katoh,et al. MAFFT Multiple Sequence Alignment Software Version 7: Improvements in Performance and Usability , 2013, Molecular biology and evolution.
[42] Y. Rosenstein,et al. Vm24, a Natural Immunosuppressive Peptide, Potently and Selectively Blocks Kv1.3 Potassium Channels of Human T Cells , 2012, Molecular Pharmacology.
[43] S. Feske,et al. Ion channels , 2013, Thorax.
[44] R. C. Rodríguez de la Vega,et al. Structure, function, and chemical synthesis of Vaejovis mexicanus peptide 24: a novel potent blocker of Kv1.3 potassium channels of human T lymphocytes. , 2012, Biochemistry.
[45] Shunyi Zhu,et al. Two dyad-free Shaker-type K⁺ channel blockers from scorpion venom. , 2012, Toxicon : official journal of the International Society on Toxinology.
[46] S. Oyama,et al. Looking over toxin-K(+) channel interactions. Clues from the structural and functional characterization of α-KTx toxin Tc32, a Kv1.3 channel blocker. , 2012, Biochemistry.
[47] H. Wulff,et al. The lymphocyte potassium channels Kv1.3 and KCa3.1 as targets for immunosuppression , 2011, Drug development research.
[48] R. Norton,et al. Analogs of the sea anemone potassium channel blocker ShK for the treatment of autoimmune diseases. , 2011, Inflammation & allergy drug targets.
[49] B. Vásárhelyi,et al. Lymphocyte activation in type 1 diabetes mellitus: the increased significance of Kv1.3 potassium channels. , 2010, Immunology letters.
[50] L. Possani,et al. Tst26, a novel peptide blocker of Kv1.2 and Kv1.3 channels from the venom of Tityus stigmurus. , 2009, Toxicon : official journal of the International Society on Toxinology.
[51] K. Chandy,et al. The functional network of ion channels in T lymphocytes , 2009, Immunological reviews.
[52] R. C. Rodríguez de la Vega,et al. A selective blocker of Kv1.2 and Kv1.3 potassium channels from the venom of the scorpion Centruroides suffusus suffusus. , 2008, Biochemical pharmacology.
[53] S. J. Kehl,et al. An activation gating switch in Kv1.2 is localized to a threonine residue in the S2-S3 linker. , 2007, Biophysical journal.
[54] S. Griffey,et al. Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases , 2006, Proceedings of the National Academy of Sciences.
[55] R. C. Rodríguez de la Vega,et al. K+ channel blockers: novel tools to inhibit T cell activation leading to specific immunosuppression. , 2006, Current pharmaceutical design.
[56] J. Tytgat,et al. A novel toxin from the venom of the scorpion Tityus trivittatus, is the first member of a new α‐KTX subfamily , 2006, FEBS letters.
[57] M. De Waard,et al. Evidence for Domain-specific Recognition of SK and Kv Channels by MTX and HsTx1 Scorpion Toxins* , 2004, Journal of Biological Chemistry.
[58] R. C. Rodríguez de la Vega,et al. Current views on scorpion toxins specific for K+-channels. , 2004, Toxicon : official journal of the International Society on Toxinology.
[59] M. Ayeb,et al. Kbot1, a three disulfide bridges toxin from Buthus occitanus tunetanus venom highly active on both SK and Kv channels , 2004, Peptides.
[60] B. Sakmann,et al. Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches , 1981, Pflügers Archiv.
[61] M. Delepierre,et al. The 'functional' dyad of scorpion toxin Pi1 is not itself a prerequisite for toxin binding to the voltage-gated Kv1.2 potassium channels. , 2004, The Biochemical journal.
[62] P. Calabresi,et al. The voltage-gated Kv1.3 K(+) channel in effector memory T cells as new target for MS. , 2003, The Journal of clinical investigation.
[63] R. C. Rodríguez de la Vega,et al. Novel interactions between K+ channels and scorpion toxins. , 2003, Trends in pharmacological sciences.
[64] R. C. Rodríguez de la Vega,et al. Two novel toxins from the Amazonian scorpion Tityus cambridgei that block Kv1.3 and Shaker B K(+)-channels with distinctly different affinities. , 2002, Biochimica et biophysica acta.
[65] Shoba Ranganathan,et al. kappa-Hefutoxin1, a novel toxin from the scorpion Heterometrus fulvipes with unique structure and function. Importance of the functional diad in potassium channel selectivity. , 2002, The Journal of biological chemistry.
[66] E. Horjales,et al. Effects of Toxins Pi2 and Pi3 on Human T Lymphocyte Kv1.3 Channels: The Role of Glu7 and Lys24 , 2001, The Journal of Membrane Biology.
[67] P. Libby,et al. CD154 (CD40 ligand). , 2000, The international journal of biochemistry & cell biology.
[68] G A Gutman,et al. A unified nomenclature for short-chain peptides isolated from scorpion venoms: alpha-KTx molecular subfamilies. , 1999, Trends in pharmacological sciences.
[69] B. Rudy,et al. Molecular Diversity of K+ Channels , 1999, Annals of the New York Academy of Sciences.
[70] E. Serfling,et al. The Interleukin 2 Receptor α Chain/CD25 Promoter Is a Target for Nuclear Factor of Activated T Cells , 1998, The Journal of experimental medicine.
[71] O. Pongs,et al. A four-disulphide-bridged toxin, with high affinity towards voltage-gated K+ channels, isolated from Heterometrus spinnifer (Scorpionidae) venom. , 1997, The Biochemical journal.
[72] R. MacKinnon,et al. Mapping the Receptor Site for Hanatoxin, a Gating Modifier of Voltage-Dependent K+ Channels , 1997, Neuron.
[73] C. Roumestand,et al. On the Convergent Evolution of Animal Toxins , 1997, The Journal of Biological Chemistry.
[74] James E. Hall,et al. Topology of the pore-region of a K+ channel revealed by the NMR-derived structures of scorpion toxins , 1995, Neuron.
[75] C. Miller,et al. Mechanism of charybdotoxin block of a voltage-gated K+ channel. , 1993, Biophysical journal.
[76] M. Garcia-Calvo,et al. Purification, characterization, and biosynthesis of margatoxin, a component of Centruroides margaritatus venom that selectively inhibits voltage-dependent potassium channels. , 1993, The Journal of biological chemistry.